Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease

Abstract

Background Troponin T is present in the blood of a majority of patients with endstage renal disease (ESRD) undergoing regular dialysis and presence of troponin T is a predictor of adverse outcome in these patients. With several new formulations of troponin I assays available, this study was performed to see whether these newer assays were able to detect troponin I in these patients more effectively than the older assays.

High sensitivity cardiac troponin assays in the clinical laboratories

“…Interestingly, allcause mortality during a median 24-month follow-up was associated with abnormal, i.e., detectable cTnT, but not with abnormal cTnI in this study [90]. However, more sensitive cTnI assays displayed similar data to the cTnT results [91].…”

Cardiac Biomarkers in End-Stage Renal Disease

“…The exact frequency of these elevations varies somewhat between studies, depending on the patient inclusion criteria, the applied cut-off values and the troponin assay used. In general, cTnT has been found elevated more often than cTnI (roughly 53% for cTnT and 17% for cTnI as reviewed in (Kanderian & Francis, 2006)) although recent publications, using more sensitive assays suggest that the frequency of cTnT and cTnI elevations are similar (Hickman et al, 2007;Kumar, Michelis, Devita, Panagopoulos, & Rosenstock, 2010). It is important to note that the number of detected cTn elevations depends on the cut-offs that are used to define elevated values.…”

Myofilament proteins: From cardiac disorders to proteomic changes

“…Degradation products of TnT were also found both in animal models of ischemia/reperfusion injury [38,39] and in serum of patients with AMI [40,41]. In 2000, TnI and TnT have been approved as the biomarkers for AMI diagnosis [42], and several kits have been commercially developed and used in clinical studies [43][44][45]. In addition to TnI and TnT, other myofilament proteins, including TnC [46], LC2 [46], aactinin [32] and MyBP-C [47], were also reported as useful markers in animal models of ischemia/reperfusion injury.…”

“…Alternatively, the degradation site can be mapped using antibody epitope analysis [62], in which an array of mAb recognizing different regions within protein sequences is used [43][44][45].…”